Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes


Diabetes Care 2024;47(8):1–23 | https://doi.org/10.2337/dci24-0042

Consensus guidance for monitoring people with islet autoantibody-positive pre-stage 3 type 1 diabetes

Who should be monitored?

Any child, adolescent or adult who has tested positive for islet autoantibodies in early-stage type 1 diabetes (T1D)

Nearly 100% of individuals in early-stage T1D with two or more persistent islet autoantibodies will progress to a stage 3 (clinical) diagnosis

What is the purpose of monitoring in early-stage T1D?

Primary purpose is to prevent DKA and minimize the risk of emergency care or hospital admission

Identification of individuals eligible to receive therapeutic intervention(s) to delay onset of stage 3 T1D and prolong β-cell function

To provide advice for the start of insulin in stage 3 T1D, when glucose is elevated and before symptoms develop, to mitigate the consequences of long-term hyperglycemia

To avoid misdiagnosis of T2D and delayed start of insulin therapy

Referral for participation in research studies

Who is involved in monitoring in early-stage T1D?

- Primary care healthcare professionals
- Pediatric and adult endocrinologists
- Diabetologists
- Diabetes behavioral health professionals
- General pediatricians
- Diabetes education specialists
- Allied healthcare professionals
- Individuals with early-stage T1D and families

Ab, antibody; DKA, diabetic ketoacidosis; IAB+, islet autoantibody-positive; PRN, pro re nata (as needed); T1D, type 1 diabetes

*Monitoring frequency and methodology depends on age, length of time since first detection of IAs, number of IAs detected and presence of symptoms of T1D
Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes

https://doi.org/10.2337/dci24-0042

Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programs are being increasingly emphasized. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody–positive (IAb+) children and adults who are at risk for (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in nonspecialized settings. To inform this monitoring, JDRF, in conjunction with international experts and societies, developed consensus guidance. Broad advice from this guidance includes the following: 1) partnerships should be fostered between endocrinologists and primary care providers to care for people who are IAb+; 2) when people who are IAb+ are initially identified, there is a need for confirmation using a second sample; 3) single IAb+ individuals are at lower risk of progression than multiple IAb+ individuals; 4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; 5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and 6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasizes significant unmet needs for further research on early-stage type 1 diabetes to increase the rigor of future recommendations and inform clinical care.

OVERVIEW

Currently, screening of individuals for islet autoantibodies is undertaken as part of programs to detect children, adolescents, and adults who are at higher risk of developing type 1 diabetes due to having a first-degree relative with type 1 diabetes or having a known high-risk HLA genotype. Periodic monitoring of people who have screened positive for one or more autoantibodies (islet autoantibody–-positive [IAb+] individuals) is largely, but not always, conducted within these cohort studies. However, up to 90% of people who develop type 1 diabetes are not part of at-risk groups. Thus, screening programs within the general population are being initiated, and guidance for monitoring in nonspecialist settings is urgently needed. The guidance provided here was developed by a series of expert working groups, convened as part of a JDRF initiative to document the aims, scope, and purpose of monitoring for children, adolescents, and adults with islet autoantibody positivity, along with recommended frequencies of monitoring and actions for health care professionals (HCPs) when risk of progression toward symptomatic type 1 diabetes is high. This includes expert clinical advice for educational and psychosocial support


1Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel 2Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel 3Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany 4Forschgruppe Diabetes, Technical University Munich, Klinikum Rechts Der Isar, Munich, Germany
for IAb+ individuals, including for their families and caregivers. The expert clinical advice for adults reflects available data, yet it is important to note that there are very limited data in adults aged 45 years and older who are IAb+. It is also impor-

5 Division of Endocrinology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
6 Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, CA
7 Breakthrough T1D, Gainesville, FL
8 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
9 Department of Endocrinology, Diabetes and Metabolism, University Medical Centre Ljubljana, Ljubljana, Slovenia
10 Charles Perkins Centre and Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
11 JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre Human Genetics, Nuffield Department of Medicine Oxford National Institute for Health and Care Research Biomedical Research Centre, University of Oxford, Oxford, U.K.
12 Department of Paediatrics, University of Oxford, Oxford, U.K.
13 Center for Regenerative Therapies Dresden, Faculty of Medicine, Technical University of Dresden, Dresden, Germany
14 Paul Langerhans Institute Dresden, Helmholtz Centre Munich at the University Clinic Carl Gustav Carus of Technical University of Dresden, and Faculty of Medicine, Technical University of Dresden, Dresden, Germany
15 The Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, U.K.
16 Department of Public Health, NHS Fife, Kirkcaldy, U.K.
17 Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia
18 Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
19 Division of Paediatrics, Women’s and Children’s Hospital, Adelaide, South Australia, Australia
20 Divison of Paediatrics & Child Health, School of Clinical Medicine, UNSW Medicine & Health, Sydney, New South Wales, Australia
21 Breakthrough T1D, Lisbon, Portugal
22 International Society for Pediatric and Adolescent Diabetes (ISPAD), Berlin, Germany
23 Diabetes & Endocrine Care Clinique Pediatrique (DECCP), Clinique Pediatrique/Centre Hospitalier (CH) de Luxembourg, Luxembourg City, Luxembourg
24 Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-Belval, Luxembourg
25 Department of Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO
26 Department of Clinical and Health Psychology, University of Florida, Gainesville, FL
27 Department of Pediatrics, University of Florida Diabetes Institute, Gainesville, FL
28 Breakthrough T1D, New York, NY
29 T1D Exchange Boston, MA
30 Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden
31 Department of Pediatrics, Skåne University Hospital, Malmö and Lund, Sweden
32 Children’s Diabetes Foundation, Aurora, CO
33 American Diabetes Association, Arlington, VA
34 NYU Langone Medical Center, New York, NY
35 Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, WA
36 Sanford Research, Sioux Falls, SD
37 Department of Pediatrics, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD
38 Pacific Northwest Diabetes Research Institute, University of Washington, Seattle, WA
39 Division of Endocrinology, University of Florida College of Medicine, Gainesville, FL
40 School of Psychology, Deakin University, Geelong, Victoria, Australia
41 The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria, Carlton, Victoria, Australia
42 Institute for Health Transformation, Deakin University, Geelong, Victoria, Australia
43 Department of Paediatrics, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, U.K.
44 Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, U.K.
45 National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, U.K.
46 Mount Sinai South Nassau, Oceanside, NY
47 Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN
48 Department of Behavioral Sciences and Social Medicine, Florida State University College of Medicine, Tallahassee, FL
49 Association of Diabetes Care & Education Specialists, Chicago, IL
50 Medical Psychology, Hannover Medical School, Hannover, Germany
51 Endocrine Society, Washington, DC
52 Division of Pediatric Endocrinology and Diabetes, University of Pittsburgh, University of Pittsburgh Medical Center Children’s Hospital of Pittsburgh, PA
53 Department of Pediatrics, Kristianstad Hospital, Kristianstad, Sweden
54 Department of Pediatrics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, U.K.
55 Department of Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium
56 Department of Family Medicine, Brody School of Medicine, East Carolina University, Greenville, NC
57 Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI
58 Center for Public Health Genomics, University of Virginia, Charlottesville, VA
59 Department of Pediatrics, University of Florida, Gainesville, FL
60 Division of Endocrinology, Long Island Jewish Medical Center, Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, New Hyde Park, NY
61 Division of Pediatric Endocrinology and Diabetology, Herman B Wells Center for Pediatric Research, Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN
62 Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL
63 Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
65 Division of Endocrinology and Diabetes, Baystate Children’s Hospital and University of Massachusetts Chan Medical School–Baystate, Springfield, MA
66 Research Unit of Clinical Medicine, Department of Pediatrics, Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland
67 The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
68 Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia
69 Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
70 Department of Pediatric Endocrinology, Rainbow Babies and Children’s Hospital, University Hospitals Cleveland Medical Center, Cleveland, OH

Corresponding author: Anastasia Albanese-O’Neill, aonell@breakthrough1d.org

Received 7 May 2024 and accepted 9 May 2024

This article contains supplementary material online at https://doi.org/10.2337/dbi24-0042.

This consensus report was endorsed by the European Society for the Study of Diabetes (EASD), American Diabetes Association (ADA), American Association of Clinical Endocrinology (AACE), American College of Diabetology (ACD), Association of Diabetes Care & Education Specialists (ACDES), Australian Diabetes Society (ADS), the International Society for Pediatric and Adolescent Diabetes (ISPAD), Advanced Technologies & Treatments for Diabetes (ATTD), DiabUnion, the Endocrine Society, and JDRF International.

This article is being simultaneously published in Diabetes Care (https://doi.org/10.2337/dc24-0042) and Diabetologia (https://doi.org/10.1007/s00125-024-02609-5) by the ADA and the EASD.

A consensus report is a document on a particular topic that is authored by a technical expert panel under the auspices of ADA. The document does not reflect the official ADA position but rather represents the panel’s collective analysis, evaluation, and expert opinion. The primary objective of a consensus report is to provide clarity and insight on a medical or scientific matter related to diabetes for which the evidence is contradictory, emerging, or incomplete. The report also aims to highlight evidence gaps and to propose avenues for future research. Consensus reports undergo a formal review process, including external peer review and review by the ADA Professional Practice Committee and ADA scientific team for publication.

© American Diabetes Association and European Association for the Study of Diabetes. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
tant to note that this consensus document does not encompass screening for islet autoantibodies and only provides expert clinical advice for monitoring of individuals who have screened positive for at least one islet autoantibody.

INTRODUCTION AND RATIONALE

The presence of islet autoantibodies for a presymptomatic period of variable duration in first-degree relatives of individuals with type 1 diabetes has been known for more than 40 years (1), with recommendations for islet autoantibody screening appearing soon after (2). Decades of subsequent research and monitoring of individuals with islet autoantibody positivity has led to the paradigm shift that type 1 diabetes is a continuum of stages, from genetic risk through to autoimmunity and then metabolic disease. This has been accompanied by the evolution of descriptive terminology that reflects these stages (Table 1). Similarly, treatment options have moved on from monitoring and managing metabolic disease to include options for modulating the autoimmune response (3,4).

Screening programs have developed to the point that large numbers of children and adults at risk of and with early-stage type 1 diabetes have been intensively followed in longitudinal cohort studies (5–15) centered on understanding the natural history of progression to symptomatic type 1 diabetes (see Table 2 for a list of studies available for participation). Of note, many entry criteria for individuals with presymptomatic type 1 diabetes into these studies require a family history of type 1 diabetes or HLA genetic risk, and most are focused on pediatric populations. Based on the outcomes of these and other studies, stages of presymptomatic and symptomatic type 1 diabetes are now clinically defined (Table 1) to a degree of clinical consensus (16–18), although regulatory agencies and research studies may differ in definitions. Using these classifications, individuals can be monitored, diagnosed with diabetes, and even, at times, started on insulin replacement therapy early in the disease course, based on meeting American Diabetes Association (ADA) (18), International Society for Pediatric and Adolescent Diabetes (ISPAD) (16), or American Association of Clinical Endocrinology (AACE) (19) diagnostic criteria. To date, the ISPAD guidelines have provided metabolic and autoantibody monitoring recommendations for children with presumptive type 1 diabetes (16) but do not make specific recommendations for education or psychosocial support in IAb+ individuals, monitoring of single IAb+ individuals, or when to start insulin. The Fr1da study has suggested and introduced specific recommendations for children (20). A separate set of recommendations based on a Delphi survey of expert opinion has provided guidance on metabolic and autoantibody monitoring, with recommendations for education and psychosocial support, but does not specifically address adults with early-stage type 1 diabetes (21). Consequently, to date there is no available guidance on monitoring in adults or in individuals with single islet autoantibody positivity or on when insulin therapy is indicated.

Consensus on evidence-based expert clinical advice for monitoring is an important unmet need, since a positive test for islet autoantibodies (Table 3) is a condition for access to disease-modifying therapies, such as teplizumab (22). In addition, islet autoantibody screening is anticipated to become more common (7,23–25), highlighting the need for clear monitoring advice.

Screening efforts are identifying an ever-growing number of IAb+ people who warrant education and ongoing monitoring for progression toward clinical diabetes. Evidence shows that such monitoring in research studies can significantly reduce the incidence of diabetic ketoacidosis (DKA) at diagnosis (24,26–33), occurring in up to 70% of unmonitored individuals, which is greatly lowered for individuals participating in follow-up studies (26,34–39). The impact of monitoring in general clinical practice on DKA rates is not known. DKA is a life-threatening condition that requires hospital admission, with significant associated costs for critical care (40–42). Additionally, in a number of studies, DKA at presentation of type 1 diabetes in youth has been associated with higher HbA1c that was sustained for up to 11 years after diagnosis (43–45). Other studies have, however, not found such an association between DKA at presentation of type 1 diabetes and higher long-term glycemic levels (46). The lack of DKA at onset of type 1 diabetes is also predictive of fewer severe hypoglycemic events 10 years after diagnosis (47). In this context, the overall goals of monitoring are described in Table 4.

Monitoring of people with islet autoantibody positivity outside of research settings will require expert clinical advice that is clear and actionable by HCPs who have limited expertise in diabetes. As indicated, current insights into monitoring progression to clinical type 1 diabetes are largely derived from research studies of individuals known to be at risk for type 1 diabetes, and general population data are less extensive. With this caveat, knowledge on best practices is particularly important for primary care and secondary care physicians who may not frequently see people known to be at risk for type 1 diabetes, and yet who will be tasked with the initial aspects of monitoring following a positive autoantibody screen. Other people who may assist with care of these individuals will include nurse practitioners, physician assistants, diabetes care and education specialists (DCES), psychologists, and other mental and behavioral health professionals, all of whom have a role in supporting IAb+ individuals and their families within the monitoring environment. Clear expert clinical advice for monitoring by these groups of HCPs increases the likelihood that individuals at risk for or in early stages of type 1 diabetes, and their families, can receive accurate and actionable education about presymptomatic type 1 diabetes and their individual status.

The Requirement for Monitoring

Islet autoantibodies against four major pancreatic autoantigens are currently clinically available; these consist of insulin autoantibody (IAA), GAD autoantibody (GADA), insulinoma antigen-2 autoantibody (IA-2A) (also called islet cell autoantigen 512 [ICA512]), and ZnT8A (48). These are often considered “biochemical autoantibodies” and are the screening targets recommended by the most recent ADA Standards of Care (25). A further islet autoantibody assay, for islet cell autoantibodies, using indirect immunofluorescence on pancreatic tissue, has been used for screening purposes, but it is less available outside of research studies, and the antigenic targets are not fully known. Considerable evidence in multiple populations supports the concept that the number and type of biochemical autoantibodies can be used to predict risk for progression to
Table 1—Staging criteria for autoantibody-positive individuals in pre-stage 1 and stage 1–3 type 1 diabetes (16–18)

<table>
<thead>
<tr>
<th>Stage of T1D</th>
<th>Islet autoantibody status</th>
<th>Glycemic status</th>
<th>Symptoms</th>
<th>Insulin required</th>
</tr>
</thead>
<tbody>
<tr>
<td>At-risk (pre-stage 1 T1D)</td>
<td>Single autoantibody or transient single autoantibody</td>
<td>• Normoglycemia</td>
<td>No symptoms</td>
<td>Not required</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• FPG &lt; 5.6 mmol/L (&lt;100 mg/dL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 120-min OGTT &lt; 7.8 mmol/L (&lt;140 mg/dL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• HbA1c &lt; 39 mmol/mol (&lt;5.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 1 T1D (also referred to as early-stage T1D or presymptomatic T1D)</td>
<td>≥2 autoantibodies</td>
<td>• Normoglycemia</td>
<td>No symptoms</td>
<td>Not required</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• FPG &lt; 5.6 mmol/L (&lt;100 mg/dL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 120-min OGTT &lt; 7.8 mmol/L (&lt;140 mg/dL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• HbA1c &lt; 39 mmol/mol (&lt;5.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 2 T1D (also referred to as early-stage T1D or presymptomatic T1D)</td>
<td>≥2 autoantibodies*</td>
<td>Glucose intolerance or dysglycemia not meeting diagnostic criteria for stage 3 T1D, with at least two of the following, or meeting the same single criteria at two time points within 12 months:</td>
<td>No symptoms</td>
<td>Not required</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• FPG 5.6–6.9 mmol/L (100–125 mg/dL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 120-min OGTT 7.8–11.0 mmol/L (140–199 mg/dL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• OGTT values ≥11.1 mmol/L (≥200 mg/dL) at 30, 60, and 90 min</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• HbA1c 39–47 mmol/mol (5.7–6.4%) or longitudinal ≥10% increase in HbA1c (66,67) from the first measurement with stage 2 T1D</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CGM values &gt;7.8 mmol/L (&gt;140 mg/dL) for 10% of time over 10 days’ continuous wear (73)† and confirmed by at least one other non-CGM glucose measurement test listed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 3 T1D</td>
<td>≥1 autoantibody</td>
<td>Persistent hyperglycemia with or without symptoms, as measured and confirmed by one or more of the following:</td>
<td>May include‡:</td>
<td>Insulin, based on glycemic status</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• One random venous glucose ≥11.1 mmol/L (≥200 mg/dL) with overt symptoms</td>
<td>• Polyuria</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 120-min OGTT ≥11.1 mmol/L (≥200 mg/dL) and/or</td>
<td>• Polydipsia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Two random venous glucose ≥11.1 mmol/L (≥200 mg/dL) and/or</td>
<td>• Weight loss</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• FPG ≥7.0 mmol/L (≥126 mg/dL) and/or</td>
<td>• Fatigue</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Laboratory-tested HbA1c ≥48 mmol/mol (≥6.5%)</td>
<td>• DKA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CGM values &gt;7.8 mmol/L (&gt;140 mg/dL) for 20% of time over 10 days’ continuous wear (73)† and confirmed by at least one other non-CGM glucose measurement test listed</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FPG, fasting plasma glucose; T1D, type 1 diabetes mellitus. *Some people with confirmed persistent prior multiple autoantibody positivity may revert to single autoantibody status or negative status (95). †Some people with confirmed persistent prior multiple autoantibody positivity may revert to single autoantibody status or negative status (95). ‡Stage 3 might not include symptoms.

clinical disease (stage 3 type 1 diabetes) (Table 1). These autoantibodies and their characteristics are described in Table 3. However, it must be noted that these attributes are derived from observations made in known IAb+ populations in the research environment. Further data from studies in IAb+ groups in the general population are needed.

Confirmation of IAb+ status is important to identify the persistence of the underlying autoimmune response and the validity of the target antigen, although the accuracy of autoantibody tests can vary between laboratories and between target antigens. Therefore, the first positive test should be confirmed with a second test within 3 months (49) and, where possible,
in a laboratory that meets the performance standards set by the Islet Autoantibody Standardization Program (IASP) (50). Persistent IAb status on two or more different samples is needed, using sensitive and specific assays with high predictive value for disease progression (51). Several research programs have tested for islet autoantibody status using capillary sampling to obtain serum or dried blood spots for assessment; however, venous samples are preferred (due to reduced interference from hemolysis) and should be used as confirmation whenever capillary testing has been performed initially.

Predicting when an individual with type 1 diabetes–related autoantibodies may progress to stage 3 type 1 diabetes is difficult. However, in children and adolescents, persistent multiple IAb+ status confirms early-stage (stage 1 or stage 2) type 1 diabetes with higher rate of progression to stage 3 type 1 diabetes compared with single IAb+ status (52). For the same reasons as discussed for single IAb+ status, confirmation of multiple IAb+ status is important, as it indicates early-stage type 1 diabetes and should adhere to the “rule of twos,” i.e., the presence of two different autoantibodies confirmed in two tests from two separate samples (51–54). Subsequent loss of individual antibodies is not associated with a slower rate of progression. The type of positive autoantibody (Table 3) is also of importance, since, as children age, relative risks for progression with each antibody type will change (55,56), with some evidence that this is also true for adults (55,57). Consideration of these data, along with autoantibody titers, may aid risk stratification (58). Although fewer data are available in adults, Type 1 Diabetes TrialNet cohort data indicate that the

### Table 2—Established population-based screening and monitoring studies in early-stage type 1 diabetes

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Study name/description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASK</td>
<td>Autoimmunity Screening for Kids program (7)</td>
</tr>
<tr>
<td>BABYDIAB</td>
<td>Part of the international Type 1 Data Intelligence (T1D) project (156)</td>
</tr>
<tr>
<td>DAISY</td>
<td>Diabetes Autoimmunity Study in the Young (6)</td>
</tr>
<tr>
<td>DIPP</td>
<td>Type 1 Diabetes Prediction and Prevention Study based in Finland (11)</td>
</tr>
<tr>
<td>DPT-1</td>
<td>Diabetes Prevention Trial–Type 1 (12)</td>
</tr>
<tr>
<td>ENDIT</td>
<td>European Nicotinamide Diabetes Intervention Trial (13)</td>
</tr>
<tr>
<td>Fr1da</td>
<td>Population-based health care research study based in Bavaria, Germany (9)</td>
</tr>
<tr>
<td>INNODIA</td>
<td>Global partnership between academic institutions, commercial partners, and patient organizations (14)</td>
</tr>
<tr>
<td>PLEDGE</td>
<td>Population Level Estimation of T1D Risk Genes in Children (155)</td>
</tr>
<tr>
<td>TEDDY</td>
<td>The Environmental Determinants of Diabetes in the Young study (5)</td>
</tr>
<tr>
<td>Type 1 Diabetes TrialNet</td>
<td>International research network centered on delaying or preventing T1D (10)</td>
</tr>
<tr>
<td>Type15Screen</td>
<td>Australian screening and monitoring program open to relatives of individuals with type 1 diabetes and IAb+ people identified through other screening pathways (ANZCTR registration no. ACTRN12620000510943)</td>
</tr>
</tbody>
</table>

Note that major research networks are included in the table, but this is not an exhaustive list. ANZCTR, Australian New Zealand Clinical Trials Registry.

### Table 3—Autoantibodies against islet autoantigens detected in stage 1–3 type 1 diabetes

<table>
<thead>
<tr>
<th>Autoantibody</th>
<th>Islet specificity</th>
<th>Typical characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>IAA</td>
<td>Insulin</td>
<td>• Common as a first detected autoantibody in young children (157,158)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Appearance is more common in younger children (159)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Frequency of appearance declines with age</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Not informative for individuals treated with insulin, who often develop antibodies in response to injected insulin</td>
</tr>
<tr>
<td>GADA</td>
<td>GAD</td>
<td>• Common as a first detected autoantibody in childhood, up until age 15 years (157,158,160)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Adult-onset cases most often present with GADA (161)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Is associated with slower progression to T1D (162)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Is often found as a single positive islet autoantibody, especially in adults</td>
</tr>
<tr>
<td>IA-2A (also known as ICAS12)</td>
<td>Tyrosine phosphatase islet antigen-2</td>
<td>Presence is associated with more advanced islet autoimmunity and faster progression to stage 3 T1D (55,163)</td>
</tr>
<tr>
<td>ZnT8A</td>
<td>Zinc transporter type 8, a transmembrane protein in the β-cell granule</td>
<td>Presence can improve risk stratification in individuals with single GADA+, IAA+, or IA-2A+ status (164)</td>
</tr>
<tr>
<td>ICA</td>
<td>Multiple antigens, undefined</td>
<td>Detected by indirect immunofluorescence on islet cell tissue. While not frequently measured other than in research studies, it does add to risk determination in the presence of other biochemical autoantibodies</td>
</tr>
</tbody>
</table>

IAA, insulin antigen-2 autoantibody; ICA, islet cell autoantibodies; ICAS12, islet cell autoantigen 512; T1D, type 1 diabetes.
rate of progression to type 1 diabetes in IAb+ adults is slower than in children (59).

Misdiagnosis of type 1 diabetes as type 2 diabetes in adolescents and adults can lead to DKA (60), as this misdiagnosis means that these individuals are often not started on insulin (61). Latent autoimmune diabetes of adults (LADA) can also be misdiagnosed as type 2 diabetes (62), with a risk of delayed insulin initiation. These observations emphasize the value of autoantibody testing for newly diagnosed adults with diabetes, particularly when they have features of type 1 diabetes (e.g., younger age, nonobese, sudden weight loss, mild acidosis, DKA, hyperglycemia >16.7 mmol/L (>300 mg/dL)) (63), for making an accurate diagnosis and starting appropriate treatment. It is, however, important to recognize that some individuals with new-onset type 1 diabetes have a phenotype that does not differ substantially from people with type 2 diabetes, particularly given the increased prevalence of obesity (60,64). Misdiagnosis of maturity-onset diabetes of the young (MODY) is also reported (65), suggesting that islet autoantibody screening can be valuable at presentation of all forms of diabetes.

An important outcome of monitoring individuals with islet autoantibody positivity is to inform the decision to initiate insulin therapy, and this is an area of evolving practice. In some centers, individuals with hyperglycemia (Table 5) but with HbA1c <48 mmol/mol (<6.5%) might not be started on insulin without the presence of symptoms. Sequential HbA1c monitoring has been productive in this context in pediatric studies on individuals with islet autoantibody positivity, since an absolute ≥10% increase from baseline, even if the HbA1c test reading stays below 48 mmol/mol (6.5%), is predictive of disease progression (66,67) within a median of 1 year. Risk of progression within 2 years following a confirmed ≥10% increase in HbA1c is lower for older individuals. This aspect of stage 3 type 1 diabetes (i.e., when to start insulin once hyperglycemia is confirmed) requires further evidence to support clinical practice to better understand the metabolic and mental health outcomes.

**What Should Be Monitored?**

It is acknowledged that the practice of monitoring of individuals with islet autoantibody positivity must accommodate different settings with diverse health care resources. In this context, there are multiple available tools for monitoring, including self-monitored blood glucose (SMBG), periodic continuous glucose monitoring (CGM), standard oral glucose tolerance test (OGTT), random venous glucose, HbA1c, and repeat islet autoantibody monitoring. In this context, serial stimulated C-peptide measurement during an OGTT can be used to assess deterioration of β-cell function and to predict risk development of type 1 diabetes (68). Since individuals who present with clinical type 1 diabetes (stage 3) often have significant residual β-cell function (69), they may benefit from therapies that can optimize prolongation of insulin secretion (70).

The pros and cons of each monitoring method are documented in Table 5. Identification of an increase in sequential HbA1c values from a baseline reading can be as informative as 2-h OGTT values in predicting risk of stage 3 type 1 diabetes in youth with genetic risk and type 1 diabetes–associated autoantibodies (66,67). Ongoing research continues to evaluate the role of CGM (including professional CGM, which is blinded to the user) in aiding in the identification of individuals, including those with a normal OGTT, who are likely to rapidly progress to stage 3 type 1 diabetes (71–73). To date, use of CGM metrics in individuals who have multiple IAb+ status has been shown to be predictive of progression to type 1 diabetes, but CGM measures are not yet as sensitive as OGTT testing (74).

**Where Should Monitoring Take Place?**

In practice, monitoring should be carried out wherever the skills and resources exist to perform the appropriate tests (Table 5). However, since many people will be monitored in primary care, there is a need to consider different intensities of monitoring consistent with resources available. The capabilities of primary care HCPs and other care providers should be applied to monitoring of early-stage type 1 diabetes without the need to refer to an expert practitioner until clinically appropriate. In primary care, this may help specify basic education about symptoms and glycemic signposts. It is understood that, compared with stage 1, monitoring in stage 2 type 1 diabetes may require more expert practitioners.

**OBJECTIVES AND METHODOLOGY**

The aim of this international consensus report is to formulate expert clinical advice, based on current evidence and expert opinion, that specifies the required monitoring and management approach for people who have been identified as having IAb+ status and pre-stage 3 type 1 diabetes, and can be used in daily clinical practice. Overall, these key principles should encompass 1) who should be monitored; 2) which end points to monitor; 3) the frequency and duration of monitoring; 4) initiation of insulin during stage 3 type 1 diabetes; and 5) how to provide psychosocial and educational support for affected individuals and families.

We acknowledge that monitoring of IAb+ individuals will occur in diverse settings, with variable resources to support effective monitoring of IAb+ individuals. Thus, a guiding principle of this consensus report is to provide advice that is straightforward and actionable within the landscape.
## Table 5—Attributes of current monitoring methods

<table>
<thead>
<tr>
<th>Method</th>
<th>Pros</th>
<th>Cons</th>
<th>Metrics obtained</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference OGTT*</td>
<td>• Gold standard in research settings</td>
<td>• Requires glucose load and 2–5 blood draws over 2 h</td>
<td>• Glycemic staging</td>
</tr>
<tr>
<td></td>
<td>• Used to stage disease and predict progression</td>
<td></td>
<td>• Risk scores for progression (DPTRS, DPTRS60, Index60, M60, M120, PLS) (94,165–169)</td>
</tr>
<tr>
<td>Standard OGTT†</td>
<td>• Similar to test for GDM: OGTT with 2 × blood draws (compared with 3 × draws in GDM test), performed routinely in clinical care</td>
<td>• Requires 2 blood draws: fasting and at 2 h</td>
<td>• 120-min OGTT-derived glucose</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• M120</td>
</tr>
<tr>
<td>Random glucose</td>
<td>• One-off sample</td>
<td>• Requires a blood draw or fingerstick test</td>
<td>• Similar to 120-min OGTT-derived glucose if obtained 2 h postprandially</td>
</tr>
<tr>
<td>Standard HbA1c test</td>
<td>• Highly specific for clinical diagnosis of stage 3 T1D</td>
<td>• Indicates 3-month mean glucose. Often normal in asymptomatic or recent-onset stage 3 T1D</td>
<td>• Risk of progression to “clinical disease”: HbA1c &gt; 39 mmol/mol (&gt;5.7%) (170)</td>
</tr>
<tr>
<td></td>
<td>• Can use capillary sample</td>
<td>• May be affected by age, non-diabetes disease states (e.g., renal, hematological syndromes)</td>
<td>• 10% rise from baseline (at first positive islet autoantibody) over 3–12 months (66,67) suggests dysglycemia and progression to stage 2 T1D</td>
</tr>
<tr>
<td></td>
<td>• Longitudinal HbA1c may be as informative as OGTT (66)</td>
<td>• Not suitable in the home setting</td>
<td>• Consider use of CGM if 10% rise in HbA1c is confirmed, or higher frequency of SMBG, to monitor risk for progression</td>
</tr>
<tr>
<td>CGM†</td>
<td>• Can be used at home</td>
<td>• Risk of anxiety for unblinded user seeing CGM fluctuations and experiencing alarms</td>
<td>• Sensitive in detecting individuals with asymptomatic stage 3 T1D and dysglycemia in stage 2 T1D (73)</td>
</tr>
<tr>
<td></td>
<td>• Can be blinded for physician review only in some regions</td>
<td>• Requires appropriate education on use and interpretation</td>
<td>• Risk of progression to “clinical disease,” i.e., 10% of time with glucose &gt; 7.8 mmol/L (&gt;140 mg/dL) has been associated with an 80% risk of progression to T1D within 12 months (72)</td>
</tr>
<tr>
<td></td>
<td>• Optimal duration of CGM wear is validated in adults and children &gt;2 years of age with diagnosed T1D, at all glycemic levels (171)</td>
<td>• Many primary care HCPs are unfamiliar with interpretation</td>
<td>• ≥5% time with glucose ≥7.8 mmol/L (≥140 mg/dL) has been associated with a 40% risk of progression to T1D within 2 years (71)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Cost and access issues</td>
<td>• Other PPV metrics not tested</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Duration of wear not validated in early-stage T1D</td>
<td></td>
</tr>
<tr>
<td>SMBG</td>
<td>• Simple to use at home</td>
<td>• Uncomfortable for users, can affect accuracy and use</td>
<td>• Immediate capillary blood glucose test result</td>
</tr>
<tr>
<td></td>
<td>• Comparatively low cost</td>
<td>• Optimal timing and frequency have not been determined</td>
<td>• 2-h postprandial measure likely of most value</td>
</tr>
<tr>
<td>C-peptide</td>
<td>• Validated measure of β-cell function</td>
<td>• Can be falsely low in hypoglycemia &lt;3.9 mmol/L (&lt;70 mg/dL), in severe hyperglycemia/DKA or after fasting, so concomitant serum glucose should be checked for interpretation</td>
<td>• A stimulated postprandial C-peptide value ≤0.2 mmol/L with IAb− status can assist with appropriately classifying diabetes type</td>
</tr>
<tr>
<td></td>
<td>• Stimulated C-peptide in research settings is valuable to assess insulin production and distinguish between T1D (or stages of T1D) and T2D</td>
<td>• Wide range of values at clinical diagnosis, including &gt;0.2 mmol/L, and persistent, but low, levels of secretion can be seen long after diagnosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Presence of C-peptide does not exclude T1D and on its own is not useful for staging or diagnosis of T1D</td>
<td></td>
</tr>
<tr>
<td>Repeat antibody testing</td>
<td>• Confirms initial IAb+* test result and progression to multiple IAb− status</td>
<td>• None</td>
<td>• Autoantibody type and single IAb+ or multiple IAb− status</td>
</tr>
</tbody>
</table>

*Continued on p. 8*
of available clinical skills and resources, wherever the monitoring will take place. The audience for this consensus document, therefore, includes 1) primary care providers; 2) endocrinologists and diabetologists; 3) DCES; 4) mental and behavioral health professionals; and 5) individuals at risk for or in early stages of type 1 diabetes and their families.

Methodology

The consensus process was initiated by the JDRF with a conference held on 21 February 2023 at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Berlin, Germany, with in-person or virtual attendance. M.P. served as Chair of the project and L.A.D. served as Vice Chair. A mission statement was created, and the attendees were invited by email from JDRF and the consensus project leadership. The initial working group comprised 61 internationally recognized physicians, nurse practitioners, clinical psychologists, and DCES with expertise in the diagnosis and care of people with early-stage type 1 diabetes. The conference was centered on monitoring of IAb+ people with early-stage type 1 diabetes, including discussions of current guidance on current best practice for monitoring, as applied by several prospective type 1 diabetes prevention trials (discussed in detail below).

Following a moderated discussion, expert participants were offered the opportunity to join at least one of four working groups, each focused on key aspects of monitoring. Each working group was chaired by two expert contributors, as noted below, and was tasked with a self-organized review of the available evidence, participation in serial online discussions, and development of core principles. The working groups were 1) monitoring in children and adolescents (Chairs: R.E.J.B. and K.J.G.); 2) monitoring in adults (Chairs: R.S.R. and J.M.W.); 3) educational needs (Chairs: K.J.B. and B.I.F.); and 4) psychosocial interventions (Chairs: K.A.D. and L.B.S.). This subsequently generated 21 separate online group discussions. Each aspect of these discussions was documented with support from JDRF team members and a medical writer. It must be noted that this document is not intended or structured as a systematic review.

On a weekly basis, from 3 May 2023 onwards, evidence-based statements and expert interpretations were drafted for review and revision. At the end of this iterative process, an agreed narrative review of the available evidence was compiled along with the expert clinical advice. Each bulleted principle was assigned a level of supporting evidence (A, B, C, or E; see Supplementary Table 1) that adheres to the evidence-grading system for Standards of Care in Diabetes—2023, published by the ADA (75). The process concluded with a conference to review and endorse the penultimate consensus report at the ADA’s 83rd Scientific Sessions in San Diego, CA. Following this meeting, a revised draft was made available for public comment, after which the consensus document was finalized. The outcomes of this process are also summarized in an algorithm that details the decision path for monitoring of IAb+ people regardless of whether they were screened as part of a research protocol or in the clinical setting for any reason (Fig. 1).

1. TERMINOLOGY

Precise and consistent language is important to facilitate clear communication and education. As the field has evolved, so has the language around multiple IAb+ status, the stages of type 1 diabetes, and associated risk of progression. It was once commonplace to refer to “risk of” and “prevention of” type 1 diabetes in individuals with multiple IAb+ status. However, the staging criteria recognize seroconversion to multiple IAb+ status as the onset of early-stage type 1 diabetes and, thus, it is not possible to both have a condition and be “at risk” for it.

Therefore, stage 1 type 1 diabetes and stage 2 type 1 diabetes (Table 1) should be referred to by their defined names or collectively referred to as “early-stage type 1 diabetes.” While the staging criteria are still becoming widely known, it may be appropriate to refer to these stages as “presymptomatic type 1 diabetes” for some audiences to highlight that these early stages exist prior to traditional, symptomatic (i.e., stage 3 type 1 diabetes) disease. Individuals with a genetic risk (based on genetic screening and/or family history) or with only single IAb+ status have pre-stage 1 type 1 diabetes and can be referred to as at risk, but individuals with multiple IAb+ status are confirmed as having early-stage 1 diabetes. It must also be clear what the focus of prevention is; for example, prevention of seroconversion, progression to dysglycemia or of stage 3 type 1 diabetes.

2. PARTNERSHIP BETWEEN PRIMARY CARE AND SPECIALIST HCPs

There is a need for primary care to take some of the early-stage monitoring and managing of IAb+ children and adults. However, staging criteria are relatively new and are unlikely to be widely known among primary care HCPs. Therefore, educational steps and materials must facilitate the partnership between primary care HCPs and secondary care. Primary care HCPs in some regions (e.g., the U.S. and Europe) are involved in screening and monitoring tasks for hypercholesterolemia and other metabolic syndromes, so the expectation is that this is possible for early-stage type 1 diabetes. A critical need is that all HCPs recognize that
Figure 1—Algorithm for monitoring of people screened positive for one or more islet autoantibodies. *Monitoring frequency and methodology depends on age, length of time since first detection of islet autoantibody, number of islet autoantibodies detected, and presence of symptoms of type 1 diabetes (see Table 1 and Tables 3–5). Ab, antibody; GP, general practitioner; PRN, pro re nata (as needed); Sx, symptoms; T1D, type 1 diabetes.
some IAb$^+$ individuals can progress rapidly, whereas others may not develop symptoms for decades. In this context, the following expert clinical advice is suggested.

**Clinical Roles and Responsibilities**

- Primary care HCPs should understand the stages of type 1 diabetes as well as methods for and suggested frequency of metabolic monitoring that can be used to prevent DKA at onset of clinical type 1 diabetes. [E]
- Primary care HCPs with a specific interest in managing people with early-stage type 1 diabetes can serve as a local referral resource for other primary care HCPs when specialist care providers are not readily accessible. [E]
- The primary care provider and specialty care provider, along with the at-risk single IAb$^+$ individual or the multiple IAb$^+$ individual with early-stage type 1 diabetes and their family, should determine which provider will have primary responsibility for metabolic monitoring and what degree of collaboration is desired. [E]
- The level of specialist engagement will need to be reassessed and may shift over time as the IAb$^+$ individual progresses through the stages of type 1 diabetes as well as when other needs and circumstances change. [E]

**Communication and Coordination of Care**

- Within a medical practice, HCPs should ensure that the medical record for a child, adolescent, or adult, who is single or multiple IAb$^+$, reflects their status and their individual plan for routine metabolic follow-up and for urgent evaluation if symptoms of hyperglycemia develop. [E]
- If an IAb$^+$ individual meets the criteria for stage 2 type 1 diabetes (Table 1), a referral should be made to a diabetologist/endocrinologist to discuss early treatment options and individualized risk of progression to clinical type 1 diabetes. [E]
- If an IAb$^+$ individual develops symptomatic hyperglycemia, an immediate consultation with, and referral to, a multidisciplinary diabetes team comprising specialists with training and expertise in diabetes is necessary. [E]

**Training and Skills Development**

- Both monitoring and education require a broader understanding of early-stage type 1 diabetes across the medical community. Inclusion of an understanding of the continuum of type 1 diabetes into all levels of medical and nursing education will require development of competencies appropriate to the role (Fig. 2). [E]

### 3. MONITORING IN CHILDREN AND ADOLESCENTS

**The Current Landscape of Monitoring Children and Adolescents in Early-Stage Type 1 Diabetes**

The following section encompasses monitoring of children and adolescents aged up to 17 years. The overall algorithm is summarized in Fig. 1. For a young person who has screened positive for multiple IAb$^+$ status, monitoring recommendations are also provided by the ISPAD (16) and the Fr1da study (20).

This expert clinical advice emphasizes the need to benchmark the glycaemic stage of disease and to offer ongoing monitoring for disease progression, which should be appropriate to the needs of the affected person and their family. At present, standard 2-h OGTT (1.75 g of glucose per kg of body weight up to 75 g maximum) is the preferred modality, particularly for inclusion in research studies, whereas less intensive methods are suggested for children or adolescents who decline to undertake OGTT or participate in a research protocol. Even in a clinical study setting, adherence with OGTT monitoring can be low (76). Given the diverse settings and resources available, among the monitoring tools identified (Table 5), HbA$_1c$ testing is not suitable outside of the clinical setting and only random glucose assessments, routine SMBG and CGM, that do not require venipuncture can be self-managed at home. Studies using CGM in small cohorts of children and youth with stage 1 or stage 2 type 1 diabetes have suggested that glucose levels $\geq 7.8$ mmol/L ($\geq 140$ mg/dL) for $>10$% of each day is associated with an 80% risk of progression to type 1 diabetes within 12 months of the CGM assessment period (72,77). In this context, risk of progression to stage 3 type 1 diabetes within 2 years of baseline CGM assessment was 40% in individuals with early-stage type 1 diabetes who spent $\geq$5% of each day with glucose $\geq 7.8$ mmol/L ($\geq 140$ mg/dL) (71). These outcomes indicate a need for more evidence to confirm the emerging value of CGM in monitoring individuals with early-stage type 1 diabetes and to understand the disease-predictive value of additional CGM metrics. This need is more pressing given that home use of CGM systems and CGM-derived glycemic metrics is being evaluated for risk stratification for healthy relatives of people with type 1 diabetes (78,79).

Monitoring at a 6- to 12-monthly cadence has been used for participants in prevention trials, depending on risk stratification. More frequent monitoring can be indicated for children who screen positive for islet autoantibodies before 3 years of age and are at high risk of progression (24,51), for example, at 3- to 6-monthly intervals, depending on staging (24). It should be noted that, among monitoring tools, not all CGM systems are generally available in all regions, or for use in very young children. For all individuals outside of the research setting, reducing the frequency of monitoring can be considered as part of a minimally burdensome approach, and modeling studies suggest this can be achieved while meeting the goal of DKA prevention on a population level (80). In this context, youth of Black race and/or Hispanic ethnicity are less likely to participate in monitoring (81).

**Monitoring for Single IAb$^+$ At-Risk Children**

Evidence from cohort studies indicates that up to 50% of children with single IAb$^+$ status revert to being islet autoantibody negative (IAb$^-$) (82,83). Children with confirmed persistent single IAb$^+$ status are not at high risk for progression compared with those with multiple IAb$^+$ status, with one population-based study indicating that the 10-year risk of progression to type 1 diabetes for persistent single IAb$^+$ children is 14.5%, with most of that progression (10%) happening in the first 2 years after becoming IAb$^+$ (51). This analysis also showed that the progression rate is higher for young children who have single IA-2A positivity (40.5%) compared with GADA positivity (12.9%) or IAA positivity (13.1%) (51); however, it must be noted that fewer than 10% of children with single IAb$^+$ status are IA-2A$^+$. Younger age (<5 years) at first
single-confirmed islet autoantibody positivity is a risk factor for progression to multiple islet autoantibody positivity, particularly during the first 2 years after seroconversion (84,85). As children age, relative risk for progression with each antibody subtype changes (56), with an increased effect for GADA with increasing age and a reduced effect for IAA (86). For young children, evidence indicates that metabolic and autoantibody monitoring frequency in the first 2 years after first detection of an autoantibody is key, as this is when spread from at-risk single islet autoantibody positivity to early-stage type 1 diabetes with multiple islet autoantibody positivity is most likely. Following confirmed single IAb+ status, the IAb+ evolution after 2 years predicts development of clinical type 1 diabetes (87). Progression to multiple IAb+ status or reversion is also highest in the first 2 years in single IAb+ preschool children, with a hazard rate of 0.3 in the first 2 years versus 0.05 for children who have been single IAb+ for >2 years (84). Among children with increased genetic risk, those who remain single IAb+ have a risk for type 1 diabetes of 1.8 per 100 person-years, children who revert to negative status have a risk of 0.14 per 100 person-years, and children who have never been IAb+ have a risk of 0.06 per 100 person-years (83). The rate of progression to multiple IAb+ status also declines with age (88).

Expert Clinical Advice for Monitoring of Single IAb+ (At-Risk) Children

- Confirm persistent single IAb+ status after first detection in a second sample, preferably in a laboratory that meets IASP standards, using two independent methods (89), and confirm negative status for other islet autoantibodies. [B]
- Islet autoantibody status and metabolic monitoring during the first 2 years after seroconversion is most critical (51,84,85,90). Ongoing metabolic monitoring is not essential beyond this 2-year period. [B]
- Children who develop type 1 diabetes at a very young age have more rapidly progressing and aggressive disease. For children aged <3 years who are single IAb+, monitor their IAb+ status every 6 months for 3 years, then annually thereafter for 3 more years. Metabolic monitoring in children aged <3 years should include random venous or capillary blood glucose and HbA1c values at the same frequency (51,84,85,87,90). If no progression, stop autoantibody and metabolic monitoring and counsel for risk of clinical disease. [B]
- For children aged ≥3 years at first positive test, monitor IAb+ status annually for 3 years. Metabolic monitoring should include annual random venous or capillary blood glucose and HbA1c testing for 3 years (51,84,85,90). If no progression after 3 years, stop autoantibody and metabolic monitoring and counsel for risk of clinical disease (51,84,85,90). [C]
- For children with single islet autoantibody positivity who revert to seronegative during autoantibody monitoring or do not progress (see above), education should be provided to their families emphasizing potential symptoms and awareness of DKA (33,91,92). [C]

Limitation
Many data on single IAb+ children are derived from groups with extended prospective follow-up and known genetic risk profiles or first-degree relatives with type 1 diabetes with limited racial/ethnic diversity.
Data on individuals in the general population are more limited, particularly in those with a single screening event.

**Monitoring for Multiple Autoantibody-Positive Children (Early-Stage Type 1 Diabetes)**

Children with confirmed multiple IAb status are at very high risk for progression to stage 3 type 1 diabetes within 15 years. Combined data from five prospective studies indicate that the 15-year risk for stage 3 type 1 diabetes is 85% for children with two islet autoantibodies and 92% for those with three islet autoantibodies, and that there is a >99% lifetime risk (87). In children with multiple islet autoantibody positivity, younger age at first islet autoantibody detection predicts more rapid progression to stage 3 type 1 diabetes (51,93). Although data on children with multiple islet autoantibody positivity identified from general population screening are derived from shorter follow-up durations, progression rates appear to be similar to those observed in relatives of individuals with type 1 diabetes enrolled in longitudinal research cohort studies (24,94).

The detection of multiple autoantibodies should be confirmed in a venous sample, within 3 months (49). However, this should not be a rate-limiting step in the monitoring or treatment process, as progression can happen rapidly in young children. Confirmation is critical, since without it there is a risk of delivering a false diagnosis of multiple IAb status, with consequent anxiety and distress for the individual. Conversely, although loss of confirmed multiple IAb status is rare and may be associated with reduced risk of progression to type 1 diabetes (95), monitoring should not be discontinued in this group.

**Expert Clinical Advice for Monitoring of Multiple IAb Children (Early-Stage Type 1 Diabetes)**

Monitoring of glucose metabolism among children with multiple IAb status is necessary to predict time to stage 3 diagnosis, identify those who may be eligible for intervention, and prevent DKA. Options for metabolic assessments include home SMBG monitoring, periodic CGM assessment, and laboratory testing for HbA1c, random venous or capillary blood glucose, and OGTT (with stimulated C-peptide assessments). It is acknowledged that there is variable access to high-quality laboratory testing facilities outside of the research setting. Where possible, the opportunity to undertake monitoring at home or in the primary care setting should be considered (Table 5).

**Expert Clinical Advice for Monitoring of Multiple IAb Children (Early-Stage Type 1 Diabetes)**

- Education must be provided to reinforce the need for and value of longitudinal monitoring to prevent DKA (33,91,92). Written instructions with relevant emergency contact details should be provided in case of type 1 diabetes symptoms and/or hyperglycemia. [E]
- Confirm persistent multiple IAb status after first detection in a second sample, preferably in a laboratory that meets IASP standards, following the rule of twos (52), preferably using two independent methods (89). [B] Where a two-test confirmation is not possible, a single blood test positive for multiple islet autoantibody status identifies a person with sufficient risk for metabolic monitoring. [E]
- In infrequent cases, for a child with previously confirmed multiple IAb status and who has reverted to single IAb or IAb− status (95), monitoring should also follow the advice below. [E]
- Metabolic monitoring should be conducted based on the staging criteria and modalities described in Tables 1 and 5. This should be undertaken when the child is healthy and not experiencing intercurrent illness. [E]
- SMBG meters and strips can be provided to all children with multiple islet autoantibody positivity or their parents. [E]
- During intercurrent illness, SMBG can be used to detect hyperglycemia. [A]
- For children with recent confirmation of multiple IAb status, an SMBG test can be performed on two different days over a 2-week period (on each day, test either fasting or postprandial) and again thereafter once every 1–3 months. See also advice below. [E]
- In children with stage 1 type 1 diabetes, HbA1c should be measured once every 3 months for children <3 years old, at least every 6 months for children 3–9 years old, and at least every 12 months for children >9 years old (93). [E] Increase in longitudinal HbA1c of ≥10%, even in the normal range (e.g., from 31 mmol/mol [5.0%] to 37 mmol/mol [5.5%]), indicates increased risk of disease progression to stage 3 type 1 diabetes within a median of 1 year (66,67). [B]
- In children with stage 2 type 1 diabetes, measures of glucose regulation should be monitored every 3 months, as above. [E]
- Longitudinal change in HbA1c of ≥10% from date of confirmed islet autoantibodies may indicate dysglycemia and disease progression (66,67), and requires the performance of an OGTT to assess type 1 diabetes stage (Table 1) in order to determine eligibility for therapy. [E]
- Random venous or capillary blood glucose should be measured at the same time as HbA1c. Rise in venous glucose in children with multiple IAb status predicts time to stage 3 type 1 diabetes (Table 1) (96). [E]
- OGTT is the established gold standard to classify stage 1, stage 2, or stage 3 type 1 diabetes [A], but if performing OGTT is not possible, obtain a 2-h postprandial capillary blood glucose after a carbohydrate-rich meal to assess for dysglycemia (86). [E]
- Monitor objective weight trends in a growing child using a growth chart, [C] which may be below the normal range during progression of type 1 diabetes. Ensure that a healthy meal plan has been maintained to preclude disordered eating behaviors as a cause of weight change. [E]
- Ten- to fourteen-day CGM can be used periodically to monitor glucose metabolism at a similar frequency as HbA1c measurement. [E] CGM should ideally be blinded to the individual wearing it and must be interpreted by trained HCPs, with education for the user and their family. [E] Criteria for CGM metrics to diagnose stage 2 or stage 3 type 1 diabetes are proposed (Table 1) and require further research.
- Stage 2 type 1 diabetes warrants referral to specialists in type 1 diabetes progression for discussion of risk and options for monitoring, wherever feasible. [E]
- In countries with approved therapeutic options for early-stage type 1 diabetes or locations with access to intervention studies (3,97), referral to a clinical center with expertise in the
specific treatment should be done when stage 2 type 1 diabetes is suspected or diagnosed. [E]

4. MONITORING IN ADULTS
The Current Landscape of Monitoring Adults Who Are at Risk of or Have Early-Stage Type 1 Diabetes
The following guidance encompasses monitoring of adults aged 18 years and over, although the advice is based on outcome data that typically reflect adults younger than 45 years of age. Data specific to adults older than this are an important unmet need. Epidemiological data show that, overall, type 1 diabetes is diagnosed more frequently in adulthood than in childhood (98–101), at a median of more than 35 years of age (102,103). Despite this, misdiagnoses of type 1 diabetes in adults remain common and are increasingly likely with age (60), setting the scene for development of DKA. In common with childhood-onset type 1 diabetes, adult-onset type 1 diabetes is associated with the presence of islet-specific autoantibodies (104–107). Although TrialNet cohort data indicate that the rate of progression to type 1 diabetes in IAb+ adults is slower than that in children, many adults with multiple IAb+ status and early-stage type 1 diabetes still develop stage 3 disease (59). While it has been suggested that progression in some adults may not occur and that some of those who do progress have only single islet autoantibody positivity, further long-term follow-up data are needed to better characterize the long-term implications of persistent autoimmunity in adults (108). For example, recent data highlight the frequent presence of islet autoimmunity in cohorts presenting with phenotypic type 2 diabetes (109).

Guidance to inform clinical monitoring practices in adults represents a considerable unmet need. There are many evidence-base gaps, including a lack of information about risk of disease progression in IAb+ adults without a family history of type 1 diabetes, particularly in individuals with non-European ancestry. Data on suggested monitoring protocols, including effectiveness in preventing DKA and adherence with monitoring, are substantially based on children and adolescents. The frequency of DKA among adults at diagnosis with type 1 diabetes is unknown but believed to be lower than that for children, given that adults may recognize and respond to symptoms of hyperglycemia and often have higher C-peptide levels at clinical diagnosis and a slower decline in β-cell function over time (110). However, incorrect assumptions leading to underdiagnosis of type 1 diabetes in adults mean many develop DKA before starting insulin therapy.

DKA incidence at clinical diagnosis can be reduced by participation in active monitoring (24,26,27). Regarding frequency of monitoring, modeling based on TrialNet data suggests that conducting approximately half the number of visits involved in a research setting (typically once every 12 months rather than every 6 months) is likely to be effective in substantially reducing the incidence of DKA to the levels seen in research studies both for children and adults (80). However, data from the TrialNet study indicate that adults 18 years and older are less likely than pediatric participants to engage with recommended monitoring using 6–12 monthly OGTT in the early phases after screening positive for autoantibodies (81). As with youth, adults of Black race and/or Hispanic ethnicity are less likely to participate with monitoring in this context (81).

Most endocrinologists and primary care HCPs will not be trained in monitoring adults with single IAb+ status or early-stage type 1 diabetes. Thus, the educational need will be significant. As with children and adolescents, monitoring in IAb+ adults must be realistic and actionable across diverse regions with different resources. HCPs are significantly burdened such that additional tasks for monitoring in pre-stage 3 type 1 diabetes must be clinically useful.

Monitors for Single Autoantibody-Positive At-Risk Adults
Frequency of monitoring can be based on the stage at which an individual with islet autoantibody positivity is diagnosed. Single IAb+ adults with dysglycemia should be monitored more frequently than those with normoglycemia. Additional risk stratification may also be possible based on other characteristics, such as age, or modifiable factors, such as abdominal obesity.

Expert Clinical Advice for Monitoring Single IAb+ (At-Risk) Adults
- Confirm persistent single IAb+ status after first detection in a second sample, preferably in a laboratory that meets IASP standards, using two independent methods (89), and confirm negative status for other islet autoantibodies. [B]
- Annual metabolic monitoring should be considered for single IAb+ adults if there are additional risk factors, including one or more of the following: first-degree relative with type 1 diabetes; elevated genetic risk for type 1 diabetes if tested; dysglycemia (e.g., impaired fasting glucose or impaired glucose tolerance); or history of stress hyperglycemia (111,112). [E]
- Although single IAb+ adults are at lower risk of progression to type 1 diabetes compared with children (59), and this risk continues to fall with increasing age, there remains a residual risk for progression. The approach to metabolic monitoring for single IAb+ adults can be informed by that applied for screening for type 2 diabetes, which is advised every 3 years for normoglycemic adults aged >35 years or who have overweight/obesity with one or more additional risk factors (18). A similar 3-year frequency is proposed for single IAb+ adults to monitor for risk of progression, which may be increased to annual monitoring with the additional risk factors identified for type 2 diabetes. [E]
- No type 1 diabetes monitoring is indicated in individuals with transient single islet autoantibody positivity who then revert to being seronegative. Screening for diabetes in this group of adults should, thereafter, follow standard-of-care guidelines for type 2 diabetes (18). [C]

Monitoring for Multiple Autoantibody-Positive Adults (Early-Stage Type 1 Diabetes)
As with monitoring in single IAb+ adults, more frequent monitoring is proposed for individuals with multiple IAb+ status if they are diagnosed with stage 2 type 1 diabetes compared with stage 1 type 1 diabetes. Risk stratification based on age, abdominal obesity, and other modifiable factors also applies.

Expert Clinical Advice for Monitoring Multiple IAb+ (Early-Stage Type 1 Diabetes) Adults
- Education must be provided to reinforce the need for and value of...
longitudinal monitoring to prevent DKA (33,91,92). Written instructions with relevant emergency contact details should be provided in case of type 1 diabetes symptoms and/or hyperglycemia. [E]

- Confirm persistent multiple IAb⁺ status after first detection in a second sample, following the rule of twos (52) and preferably using two independent methods (89). [B] Where a two-test confirmation is not possible, a single blood test positive for multiple islet autoantibody status identifies a person with sufficient risk for metabolic monitoring. [B]

- In infrequent cases, for adults with previously confirmed multiple IAb⁺ status who have reverted to single IAb⁺ or IAb⁻ status (95), monitoring should also follow the advice below. [E]

- All multiple IAb⁺ adults can be provided with SMBG meters and strips to be used during illness or when symptoms may be present. [E]

- In adults with stage 1 type 1 diabetes and normoglycemia (Table 1), glycemic status should be monitored using HbA₁c every 12 months as part of routine primary care visits. Modify frequency of monitoring based on individual risk assessment, based on age, number and type of islet autoantibodies, and glycemic metrics (4). [E]

- If duration of normoglycemia extends to 5 years, metabolic monitoring every 2 years may be sufficient. [E]

- In adults with confirmed stage 2 type 1 diabetes (Table 1), metabolic status should be monitored using HbA₁c every 6 months, in conjunction with one other of the following monitoring modalities: blinded CGM (applied and interpreted by trained HCP); higher frequency of SMBG; or 2-h plasma glucose following 75-g OGTT. [E]

- Longitudinal change in HbA₁c of ≥10% from date of confirmed islet autoantibodies may indicate dysglycemia and disease progression (66,67), and it requires the performance of an OGTT to assess type 1 diabetes stage (Table 1) to determine eligibility for therapy. [E]

- When dysglycemia or hyperglycemia occurs, C-peptide monitoring should be considered where the diagnosis of type 1 diabetes versus type 2 diabetes is unclear. Meta-analysis indicates that a C-peptide level of ≤0.20 nmol/L with IAb⁺ status can be associated with a diagnosis of type 1 diabetes rather than type 2 diabetes (113); however, many adults presenting with type 1 diabetes will have C-peptide above this level (110). [B]

- Note that C-peptide levels can be falsely low in hypoglycemia (<3.9 mmol/L [<70 mg/dL]), after fasting, or in severe hyperglycemia/DKA, so concomitant plasma glucose concentration should be checked and interpreted in combination with the clinical state.

- In countries with approved therapeutic options for early-stage type 1 diabetes or locations with access to intervention studies (3,96), referral to a clinical center with expertise in the specific treatment should be done when stage 2 type 1 diabetes is suspected or diagnosed. [E]

5. WHEN TO START INSULIN

At some point, monitoring will reveal a person with persistent and/or recurrent hyperglycemia, prompting a decision on whether to start insulin, along with associated education and support for affected individuals and their families. As screening programs identify more people with early-stage type 1 diabetes, more people are being assessed as meeting classic diagnostic criteria for stage 3 type 1 diabetes (Table 1) but who might not yet require insulin therapy. Decisions about how and when to initiate insulin will be based on a range of factors, many of which do not have a body of evidence. Therefore, consideration of starting insulin should trigger a referral to a specialist center with expertise in initiating and managing people with type 1 diabetes on insulin.

6. EDUCATION

The primary goals of education for the care of IAb⁺ individuals and their families are outlined in Table 7. Given the paucity of evidence on education for people with early-stage type 1 diabetes, extensive experience in education for stage 3 type 1 diabetes can be extrapolated to this population. National standards for diabetes self-management education and support (DSMES) have been published by the ADA and the Association of Diabetes Care & Education Specialists (ADCES) and are broadly applicable in this context (119). When appropriate, evidence from studies in stage 3 type 1 diabetes is used to support grading of evidence.

Experience in clinical studies can also inform education for people with early-stage type 1 diabetes and their families/caregivers. The Environmental Determinants of Diabetes in the Young (TEDDY) prospective
study protocol emphasizes parental education regarding symptoms and signs of diabetes. For families new to type 1 diabetes, this education provides foundational skills for diabetes management that are a component of reduced parenting stress at the time of stage 3 diagnosis compared with individuals who were members of the community control group and did not receive education (120). Similarly, families of children with early-stage type 1 diabetes in the Fr1da study are invited to participate in an educational program of blood glucose monitoring and symptoms of hyperglycemia/DKA. They are also provided with a guidebook specifically designed for children with early-stage type 1 diabetes and assigned a contact person to answer questions at any time. Children who take part in this program alongside metabolic monitoring have a lower rate of DKA and reduced HbA1c at stage 3 type 1 diabetes presentation compared with children who declined education and follow-up (33). Over 50% had no symptoms at the clinical presentation of stage 3 type 1 diabetes, 93.5% had no weight loss, and length of stay in hospital was shorter (91,92).

Basic community awareness campaigns not associated with monitoring and centered on the early symptoms of type 1 diabetes that target teachers, pediatricians, and parents have been effective in reducing DKA rates in children in regional settings (Parma in Italy [121] and Newcastle in New South Wales, Australia [122]). However, national campaigns in Italy and Austria, with the same objectives, have not seen the same impact (123,124). The content and delivery of these campaigns were not similar, so it is hard to draw conclusions about the effectiveness of this education.

Education topics and intensity for people with early-stage type 1 diabetes and their families should be based on type 1 diabetes stage, age, rate of progression, etc. First-degree relatives may have different needs for support and guidance from the general population, as they have an established awareness of the implications and impact of IAb status. Education topics should be linked to specifically timed action plans and include the topics detailed below. Education can be tailored so it is uniquely appropriate for both stage 1 and stage 2 type 1 diabetes (Table 1). Clinical practitioners with experience in early-stage type 1 diabetes should be involved in the later steps of education.

When Should Education Be Provided?
The needs for education are centered on the key moments in the life of the person with early-stage type 1 diabetes (119). These are at the point of a positive autoantibody screen, at diagnosis of each

---

Table 6—Selected unmet needs for further research and clinical development

<table>
<thead>
<tr>
<th>Unmet research needs</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Long-term rates of progression to stage 3 diabetes in IAb− individuals without a family history of T1D and progression rates in adults and people of non-European ancestry.</td>
</tr>
<tr>
<td>• The impact of pregnancy in women who are IAb+ and the glycemic changes that may be evident during pregnancy and in the postpartum period, along with risks for progression to stage 3 T1D during and after pregnancy.</td>
</tr>
<tr>
<td>• Neonatal outcomes for infants of women who are IAb+ and the association with glycemic changes during pregnancy.</td>
</tr>
<tr>
<td>• Cost-effectiveness of monitoring strategies for individuals with early-stage T1D.</td>
</tr>
<tr>
<td>• Timing of insulin initiation in people with presymptomatic T1D, including short- and long-term metabolic and mental health outcomes of different strategies.</td>
</tr>
<tr>
<td>• Impact of education alone, independent of other monitoring activities, on frequency of DKA at diagnosis and presentation of T1D.</td>
</tr>
<tr>
<td>• Methods of identifying and monitoring behavioral health needs in early-stage T1D.</td>
</tr>
</tbody>
</table>

---

Table 7—The primary goals of education for care of IAb+ individuals and their families

<table>
<thead>
<tr>
<th>Primary goals of education for care of IAb+ individuals and their families</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. To prevent DKA and promote safe monitoring practices and reduce the occurrence of symptoms of diabetes.</td>
</tr>
<tr>
<td>2. To minimize the requirement for emergency care, hospital admission and need for intensive care at diagnosis of T1D.</td>
</tr>
<tr>
<td>3. To improve appropriate risk perception at each monitoring milestone.</td>
</tr>
<tr>
<td>4. To understand specific outcomes, e.g., prevention of DKA, initiation of insulin therapy.</td>
</tr>
<tr>
<td>5. To understand available interventions.</td>
</tr>
<tr>
<td>6. To explore and understand the benefits of individual participation in research studies.</td>
</tr>
<tr>
<td>7. To provide education that supports psychosocial interventions to optimize general health and mental health for affected individuals and their families.</td>
</tr>
</tbody>
</table>

T1D, type 1 diabetes.
stage, when monitoring tasks are performed, and annually for review and maintenance. Education is also critical during life transitions and milestones and when care needs change.

**Key Education Topics**

Education and self-care behaviors for individuals at risk for or with early-stage diabetes (Table 1) can be derived from the overall framework of self-management skills for diabetes and related conditions. These are described in the ADCES7 self-care behaviors (125). Those relevant for at-risk individuals or those with early-stage type 1 diabetes focus on understanding the implications of their single (at-risk) or multiple (early-stage type 1 diabetes) IAb\(^+\) status and the benefits of regular monitoring. Symptom awareness and metabolic monitoring are important to reduce the risks of hospitalization for DKA. If other family members have type 1 diabetes, HCPs should not assume preexisting awareness and knowledge. The most current education should always be mandated.

**Educational Topics of Highest Value for IAb\(^+\) Individuals and Family Members**

For an individual who has tested positive for one or more autoantibodies, a person-centered plan should be developed that is best suited to the IAb\(^+\) person and their individual situation. Their family members should be included as part of the program of education. The topics that may have high value are likely to include the following: 1) understanding autoimmunity and the confirmation of single (at-risk) or multiple (early-stage type 1 diabetes) IAb\(^+\) status; 2) definition of at-risk or early-stage type 1 diabetes; 3) risk perception (accurate risk perception is linked with staying engaged in monitoring and with DKA prevention (126)); 4) risks and benefits of individual participation in research studies; 5) awareness of hyperglycemia episodes for introducing insulin at the right time; 6) strategies for healthy coping; 7) symptom awareness and prevention of DKA; 8) glucose monitoring (SMBG, CGM), if clinically recommended; 9) healthy behaviors, including meal planning and physical activity; 10) risks and benefits of intervention therapies; 11) monitoring planning, with descriptions of laboratory tests and devices that may be used (Table 5); and 12) treatment options and introduction to insulin therapy.

**Where Should Education Be Provided?**

Education should be widely accessible via a variety of modalities, across multiple media platforms and settings, and should be crafted with the specific audience’s learning needs in mind. For education aimed at HCPs, a key requirement is for professional associations in all regions to be aligned with the educational program and curriculum, preferably compatible with their educational platforms and with accreditation. For education aimed at people with pre-stage 3 type 1 diabetes, in-person options associated with clinical appointments or in-group sessions are important, and strong evidence supports DSMES delivery through virtual, telehealth, telephone, text messaging, and web-based/mobile phone applications (apps) (127–131).

**Who Should Provide Education?**

The competencies that must be addressed in education are outlined in Fig. 2. There is a need for diabetes professional associations to endorse the educational goals, educational tools, and educational content, as described. Different groups of individuals, including HCPs, community members, and individuals in need of monitoring and their families (indicated in the pyramid sections in Fig. 2), should have the competencies described and participate as appropriate.

**Expert Clinical Advice for Education of Single IAb\(^+\) (At-Risk) and Multiple IAb\(^+\) (Early-Stage Type 1 Diabetes) Individuals**

- Education is the responsibility of all health professionals involved in the monitoring and care of individuals with type 1 diabetes. [E]
- People who are at risk or with early-stage type 1 diabetes may participate in monitoring education programs to reduce the rate of DKA at diagnosis (33,90,91). [B]
- Education should be provided 1) at the point of a positive autoantibody screening; 2) at diagnosis of each stage; 3) annually for review and maintenance; and 4) during life transitions. [E]
- Education should accompany the implementation of all monitoring plans; this includes home glucose testing and any monitoring devices. [E]
- Education should be culturally, linguistically, and socioeconomically congruent. [E]
- Education topics and intensity should be based on type 1 diabetes stage and risk of progression and include the risks and benefits of intervention therapies, when appropriate. [E]
- Diabetes education should be accessible, engaging, and person centered. This includes consideration of the developmental, social, emotional, cultural, and linguistic needs of the individual and/or their family. [E]

### 7. PSYCHOSOCIAL SUPPORT

**What Is the Current Landscape Regarding Psychosocial Support for People With Type 1 Diabetes—Related Autoantibodies?**

People who learn that they or a loved one have type 1 diabetes–related autoantibodies often experience significant stress (132). This is in part because events that are unpredictable, uncontrollable and threatening may be highly stressful. People who have islet autoantibody positivity, particularly those who have multiple islet autoantibody positivity, will very likely develop type 1 diabetes in the future. However, disease progression is impossible to predict precisely and having IAb\(^+\) status does not mean imminent type 1 diabetes onset (133,134); stage 3 type 1 diabetes, with associated insulin administration and glycemic monitoring, could be months or even years away (17).

When learning they have type 1 diabetes–related autoantibodies, individuals of all ages and their family members can experience a range of emotional and behavioral reactions (135,136), including shock, grief, guilt, anger, depression, and anxiety. If time passes with no diagnosis of stage 3 type 1 diabetes, cognitions about type 1 diabetes may change and individuals may become convinced they will never get the disease or have reduced risk, despite evidence to the contrary (137). Parents often engage in behaviors in attempts to prevent type 1 diabetes when faced with the news that their child is at increased risk, even when not provided with recommendations to do so, though more recent data have shown that lower physical activity and meal plans with a higher glycemic index are associated with faster progression to type 1 diabetes (138–140). Meal-planning changes...
are most commonly reported, with extra monitoring at home (including blood glucose checking) being particularly common in families with someone who already has type 1 diabetes (141,142).

Research has documented the psychosocial impact of newborn screening (143) as well as genetic and islet autoantibody screening for type 1 diabetes (132,136). Failure to understand the screening and risk information presented is common. For example, more than a third of participating mothers and over half of participating fathers in the TEDDY study stated that their child was not at increased risk for type 1 diabetes, despite being clearly informed of their child’s increased genetic risk (137). To date, no data are available on how children screened positive for islet autoantibodies perceive or react to their risk.

Emotional distress in response to a positive islet autoantibody screen is also common. Many parents of children in the TEDDY study experienced anxiety after learning that their child was at increased risk for developing type 1 diabetes, with mothers reporting higher anxiety than fathers (132). Although anxiety decreased across time for parents of IAb+ children who never developed additional autoantibodies, anxiety remained elevated in many parents of children with multiple autoantibodies for years after the child’s first IAb+ test result. Mothers who experienced negative interpersonal life events and postpartum depression, but who were accurate about their child’s type 1 diabetes risk, were particularly vulnerable to heightened anxiety (144). In the Autoimmunity Screening for Kids (ASK) study, which conducted islet autoantibody screening in the general population, 74.4% of parents reported significant levels of anxiety about their child’s type 1 diabetes risk at the first follow-up visit; parents with lower educational attainment were more likely to exhibit higher levels of anxiety (145).

Around 40% of mothers and 20% of fathers in the Fr1da study reported clinically elevated symptoms of depression after learning that their child was at increased risk for type 1 diabetes compared with around 18% of mothers and fathers of children who were IAb− (24). Depressive symptoms declined across 1 year, with scores in mothers of IAb+ children remaining slightly elevated compared with mothers of IAb− children; scores in fathers did not remain elevated.

Although both the ADA and ISPAD have published recommendations about the psychosocial care of individuals with stage 3 type 1 diabetes (146–148), these are limited to general principles for care of those with early-stage type 1 diabetes (149). Thus, there is an urgent need to provide guidance on psychosocial support for individuals with type 1 diabetes–related autoantibodies and their families.

We recognize regional differences in health care resources may limit mental health resources for care of people with diabetes. In most areas, there are insufficient mental and behavioral health professionals with expertise in the psychosocial aspects of type 1 diabetes who can provide the care recommended by the ADA and ISPAD (146–148).

What Is the Purpose of Psychosocial Support?
The overall goal of providing psychosocial support for individuals identified as having early-stage type 1 diabetes and their families is to assist them in successfully managing the psychosocial impacts associated with this life-changing news. To accomplish this goal, emotional, cognitive, and behavioral functioning need to be assessed and addressed not only in individuals with type 1 diabetes–related autoantibodies but in their family members as well, when appropriate.

What Type of Support Should Be Provided?
The essential first step is to ask the individual who is at risk for type 1 diabetes and/or their caregivers and family members about their reactions upon receiving the news that they have type 1 diabetes–related autoantibodies. However, asking once is not enough, as adjustment to autoantibody status may change over time (132). Inquiring about how individuals are coping with the news and their current needs should be conducted at every monitoring visit. Examples of questions to include in the conversation include:

1. How do you feel about this news?
2. Others have said this news brings feelings of sadness or worry, what are your feelings?
3. What is your understanding about having multiple autoantibodies?
4. What type of things are you doing to try to prevent type 1 diabetes?
5. What are your thoughts about talking with a counselor about your feelings from this news?

Providers can also assess global symptoms of anxiety and depression using age-appropriate standardized and validated questionnaires, such as the Patient Health Questionnaire-9 (PHQ-9) for depression (150) or the Hamilton Anxiety Scale (151). However, global measures of anxiety and depression may not be sensitive to the emotional impact specifically associated with learning that one—or a loved one—has type 1 diabetes autoantibodies. In such cases, measures that assess emotional reactions to the IAb+ status, such as the “State” component of the State-Trait Anxiety Inventory (152), may be more appropriate. At a minimum, HCPs should have conversations with individuals about their reactions to IAb+ results rather than relying solely on global measures of psychosocial functioning. Assessments should occur at regular intervals, since reactions are likely to change over time. Additional measures for both depression and anxiety in diabetes are provided in the ADA psychosocial care for people with diabetes position statement (147), along with a directory of mental health providers (https://my.diabetes.org/health-directory) (153).

It is also important to consider developmental and family-specific factors when assessing psychosocial needs. For example, children and adolescents with type 1 diabetes autoantibodies may experience varied emotional, cognitive, and behavioral impacts as they develop. This further emphasizes the need for ongoing, regular assessment of psychosocial needs. Additionally, individuals with a family history of type 1 diabetes may react differently to learning about type 1 diabetes–related autoantibodies (141) compared with those who are unfamiliar with the disease; family context and prior experience with type 1 diabetes are important considerations when assessing psychosocial impact and the need for additional support.

Although increased anxiety and depression can occur in individuals with type 1 diabetes–related autoantibodies and their family members, this can be reduced by monitoring for the potential development of type 1 diabetes (120). Providing individuals with regular monitoring for type 1 diabetes, depending on stage, as outlined in earlier sections of
this statement, can help individuals manage some of the unpredictability of type 1 diabetes development (120,132).

Based on the extant literature, diabetes-focused organizations, such as the ADA and ISPAD, have provided recommendations on the importance of individuals with diagnosed type 1 diabetes receiving psychosocial care (146–148) that is preferably integrated into routine diabetes visits and delivered by providers with diabetes-specific training (154). While the same level of evidence does not yet exist in those individuals with type 1 diabetes–related autoantibodies, the well-documented emotional, cognitive, and behavioral impacts of autoantibody status certainly suggest that a similar standard for psychosocial care should be available for all individuals who are at risk for developing type 1 diabetes and their families. For individuals with early-stage type 1 diabetes and their family members, there are well-developed models of managing psychosocial reactions to risk status, including age-specific education and assigned contact people to answer questions, who can also serve as role models (9,145).

Ideally, psychosocial care should be integrated with routine monitoring visits and delivered by HCPs using a collaborative, person-centered, culturally informed approach. When available, refer to mental and behavioral health professionals with expertise in type 1 diabetes for additional assessment and treatment. For individuals residing in the U.S., the ADA publishes the Mental Health Provider Directory, which lists providers with expertise in diabetes (153).

**Expert Clinical Advice for Psychosocial Support for Single IAb (At-Risk) and Multiple IAb (Early-Stage Type 1 Diabetes) Individuals**

- Emotional, cognitive, and behavioral functioning should be assessed in people at risk or with early-stage type 1 diabetes and their family members, when appropriate. Anxiety, risk perception, and behavior changes should specifically be assessed. [E]
- As an essential first step to providing psychosocial support, HCPs should ask the individual at risk or with early-stage type 1 diabetes and/or their caregivers and family members about their reactions upon receiving the news that they have type 1 diabetes–related autoantibodies. This can be accomplished using guiding questions and standardized and validated questionnaires. [E]
- At each monitoring visit, there should be enquiries into current needs, particularly coping. [E]
- Psychological care should be integrated into routine medical visits and, whenever possible, delivered by providers with diabetes-specific training. [E]

**8. UNMET NEEDS FOR FURTHER RESEARCH**

This consensus document for monitoring individuals with single (at-risk) and multiple (early-stage type 1 diabetes) islet autoantibody positivity covers key principles based on existing evidence and agreed expert opinion. It also highlights the significant unmet need for further research on early-stage type 1 diabetes to further increase the rigor for future guidance and recommendations, and drive the evolution of clinical care for people who have tested positive for islet autoantibodies. The key principles in this consensus document will be subject to updating once additional evidence becomes available, as indicated in Table 6.

**Acknowledgments.** The author group thanks JDRF for organizing the initial expert conference and for providing funding to Robert Brines, BITE Medical Consulting (Cambridge, U.K.), who supported the author group by collating and compiling author feedback and revisions during the manuscript drafting process. The authors acknowledge the review and endorsement of the following organizations: Advanced Technologies & Treatments for Diabetes (ATTD), the American Association of Clinical Endocrinology (AACE), the American College of Diabetology (ACD), the American Diabetes Association (ADA), the Association of Diabetes Care & Education Specialists (ADCES), the Association for the Endocrine Society, the Australian Diabetes Society (ADS), Dia-Union, the European Association for the Study of Diabetes (EASD), the International Society for Pediatric and Adolescent Diabetes (ISPAD), and JDRF International.

**Duality of Interest.** M.P. has received honoraria for participation on advisory boards for AstraZeneca, Eli Lilly, MannKind Corp., Medtronic Diabetes, Pfizer, Sanofi, Dompé, LifeScan, Novo Nordisk, Insulet, Provention Bio, Merck, Ascenia Diabetes Care, Bayer, Embecta, and Tandem Diabetes Care and as a speaker for Eli Lilly, Medtronic Diabetes, Novo Nordisk, Pfizer, Sanofi, and Ascensia Diabetes Care. M.P. owns stocks of DreaMed Diabetes and NG Solutions, and his institution has received research grant support from Eli Lilly, Medtronic Diabetes, Novo Nordisk, Pfizer, Sanofi, DreaMed Diabetes, NG Solutions, Dompé, Lumos, GWave, OPKO, Prevention Bio, and AstraZeneca, travel expenses from Medtronic Diabetes and Sanofi, and consulting fees from Quib Lab and Medical and Prevention Bio. T.B. served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, Medtronic, Abbott, and Indigo Diabetes. T.B. received honoraria for participating on speakers bureaus for Eli Lilly, Novo Nordisk, Medtronic, Abbott, Sanofi, Dexcom, Adventis, AstraZeneca, and Roche. T.B.’s institution has received research grant support and travel expenses from Abbott, Medtronic, Novo Nordisk, Sanofi, Novartis, Sanoz, and Zealand Pharma. R.E.J.B. has received consulting fees from Prevention Bio.

H.M.C. has received research grant support from IQVIA, JDRF, Chief Scientist Office, Diabetes UK, and the UK Medical Research Council. H.M.C. has received honorarium from Novo Nordisk and owns shares in Roche Pharmaceuticals and Bayer AG. T.D. has received honoraria and speaker honoraria and funding fees. T.D. and his former institution has received research support from Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk, Prevention Bio, Sanofi, and Vertex Pharmaceuticals. He is a shareholder in DreamMed, Ltd. K.D. has received honorarium for participation on advisory boards for Medtronic and Novo Nordisk and speaker fees from Abbott, Eli Lilly, Novo Nordisk, Medtronic, and Pfizer. O.E. has received research support from Mannkind Corp., Medtronic Diabetes, Abbott, Dexcom, Eli Lilly Pharmaceuticals, Janssen Pharmaceuticals, and Vertex Pharmaceuticals. O.E. has also participated on advisory boards for Medtronic and Sanofi. O.E. has received consultation and speaker fees from Medtronic Diabetes, Sanofi, and Vertex. All financial support from industry for O.E. has been through his organization, T1D Exchange. R.A.G. has received honorarium from Lark, Sweetpea, Startup Health, Vida, and ValenHealth. C.J.G.’s institution received payment from Sanofi as a clinical trial center. K.J.G. has received sponsored travel from JDRF. W.H. has received grant/consultancy fees from Sanofi/Prevention Bio. M.J.H. has received grants or consultancy fees from Sanofi, MannKind Corp., and SAB Biopharmaceuticals and is a stock options holder of SAB Biopharmaceuticals. R.I.G.H. has received honoraria for speaking from EASD, Eli Lilly, ENCORE, Libereum, Novo Nordisk, Rovi, and Boehringer Ingelheim. R.I.G.H. has received conference funding from Novo Nordisk and Eli Lilly. O.K. has received honoraria and lecture fees from Sanofi, Dexcom, and Medtronic. R.W.L. has received a consultancy fee from Cigna Insurance. D.M.M. has received research support from the National Institutes of Health, JDRF, National Science Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust; and his institution has had research support from Medtronic, Dexcom, Insulet, Biologics, Tandem Diabetes Care, and Roche. C.M. serves or has served on advisory panels for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Boehringer Ingelheim, Roche, Medtronic, Imcysc, Insulet, Biomea Fusion, and Vertex Pharmaceuticals. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for C.M.
from Medtronic, Imcyse, Novo Nordisk, Sanofi, and ActoBio Therapeutics. C.M. serves or has served on speakers bureaus for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic, and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. C.M. is president of EASD. All external support of EASD is to be found on www.easd.org. H.K.O./D. received compensation from Sanofi for attending their advisory board and for speaking at ADA 84th Scientific Sessions. R.P.B. has received payment or honoraria from Bayer, Lexicon Pharma, Novo Nordisk, Avertias Pharma, Nevro, Roche, and Medtronic. M.J.R. has received honoraria and grants from Sanofi. K.M.S. has received consultancy fees, grants, or honoraria from Provention Bio and Sanofi. E.K.S. has received consulting fees from Sanofi and DRI HealthCare and has received payment for lectures from Health Matters CME, Medscape, Med Learning Group LLC, and the ADA. J.S.S. has been a scientific advisory board member for 4immune, ActoBiotics, Avotres, and Quell Therapeutics. J.S.S. has been a data safety board member for Imcyse and Provention Bio and is a member of the board of directors for SAB Therapeutics. J.S.S. has been an advisor or consultant for ImmunoMolecular Therapeutics, Novo Nordisk, Remedy Plan, Inc., SAB Therapeutics, and Sanofi. J.S.S. has shares of or is an option holder for 4immune, Avotres, ImmunoMolecular Therapeutics, Remedy Plan, Inc., and SAB Therapeutics. C.S. has received research funding from Coure Pharmaceuticals and consultancy fees from Sanofi and GentilBio. L.A.D. has received research support to their institution from Docpine, Lilly, MannKind Corp., Medtronic, Provention/Sanofi, and Zealander and consultancy fees from Vertex Pharmaceuticals and Abata. L.A.D. has a patent pending for difluoro- methylornithine (DFMO). No other potential conflicts of interest relevant to this article were reported.

Author Contributions. All listed authors were responsible for drafting the consensus guidance article and reviewing it critically for important intellectual content. All authors approved the final draft version of the manuscript submitted for publication.

Prior Publication. Parts of this work were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes Conference, Florence, Italy, 6–9 March 2024, and at the ADA 84th Scientific Sessions, Orlando, FL, 21–24 June 2024.

References

34. Winkler C, Schober E, Ziegler A-G, Holt RW. Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for...
diabetes in autoantibody positive children. J Clin Endocrinol Metab 2019;104:3337–3344
89. Bonifacio E, Predicting type 1 diabetes using biomarkers. Diabetes Care 2015;38:989–996
90. Bingley PJ, Bouwland DC, Krischer JP. Type 1 Diabetes TrialNet Study Group. The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia 2016;59:542–549
100. Greenbaum CJ, Beam CA, Beam CA, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61:2281–2287


140. Lamb MM, Frederiksen B, Seffert JA, Kroehl M, Reusers M, Norris JM. Sugar intake is associated with progression from islet autoimmunity to type 1 diabetes: the Diabetes Autoimmunity Study in the Young, Diabetesologia 2015;58:2027–2034


169. Sosenko JM, Skyler JS, Palmer JP, Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The development, validation, and utility of the Diabetes Prevention Trial-Type 1 risk score (DPTRS). Curr Diab Rep 2015;15:49


171. Raghinaru D, Calhoun P, Bergenstal RM, Beck RW. The optimal duration of a run-in period to initiate continuous glucose monitoring for a randomized trial. Diabetes Technology Ther 2022;24:868–872